...
首页> 外文期刊>Journal of pain and symptom management. >Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors
【24h】

Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors

机译:坚持测量血液恶性肿瘤与实体瘤患者的关怀事项

获取原文

摘要

Context: Measuring What Matters (MWM) prioritizes quality measures in palliative care practice. Hematologic malignancy patients are less likely to access palliative care, yet little is known about their unique needs. Differences in MWM adherence may highlight opportunities to improve palliative care in hematology. Objectives: To assess adherence to MWM measures by palliative care clinicians caring for patients with hematologic malignancies, compared to those with solid tumors. Methods: We used the Quality Data Collection Tool to assess completion of MWM measures across nine sites. Results: We included data from 678 patients' first visits and various care settings; 64 (9.4%) had a hematologic malignancy, whereas 614 (90.6%) had a solid tumor. Hematology patients were more likely to be seen in a hospital (52 or 81.3% vs. 420 or 68%), whereas solid tumor patients were more frequently seen at home or in clinics (160 or 26% vs. 7 or 10.9%). Of the nine MWM measures we assessed, high adherence (>90%) was seen regardless of tumor type in measures #3 (Pain Treatment), #7 (Spiritual Concerns), #8 (Treatment Preferences), and #9 (Care Consistent With Preferences). Clinicians seeing hematology patients were significantly less likely to meet measures #2 (Screening for Physical Symptoms; 57.8% vs. 84.2%, P < 0.001), and #5 (Discussion of Emotional Needs; 56.3% vs. 70.0%, P = 0.03). Conclusion: MWM adherence regarding symptom assessment and meeting emotional needs was lower for patients with hematologic malignancies compared to those with solid tumors. This finding suggests two key areas for quality improvement initiatives in palliative care for patients with hematologic malignancies.
机译:背景:在姑息治疗实践中,“重要事项”(MWM)优先考虑质量措施。血液系统恶性肿瘤患者较少接受姑息治疗,但对其独特需求知之甚少。 MWM依从性的差异可能会突出显示改善血液学姑息治疗的机会。目的:评估姑息治疗临床医生与实体瘤患者相比,对血液系统恶性肿瘤患者的依从性。方法:我们使用质量数据收集工具评估了九个地点的MWM措施的完成情况。结果:我们纳入了来自678位患者的首次就诊和各种护理环境的数据; 64例(9.4%)患有恶性血液病,而614例(90.6%)患有实体瘤。血液科患者更有可能在医院内就诊(52或81.3%比420或68%),而实体瘤患者则更常在家中或诊所就诊(160或26%对7或10.9%)。在我们评估的9项MWM措施中,无论在#3(疼痛治疗),#7(精神关注),#8(治疗偏好)和#9(护理一致)中,无论肿瘤类型如何,均观察到了高依从性(> 90%)带有首选项)。看到血液病患者的临床医生不太可能接受措施#2(筛查身体症状; 57.8%vs. 84.2%,P <0.001)和#5(情绪需求讨论; 56.3%vs. 70.0%,P = 0.03) )。结论:与实体瘤患者相比,血液系统恶性肿瘤患者在症状评估和满足情绪需求方面的MWM依从性较低。这一发现提出了血液恶性肿瘤患者姑息治疗质量改进计划的两个关键领域。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号